Agios Pharma (AGIO) Misses Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. QGEN
10. KNX

Go back to Agios Pharma (AGIO) Misses Q4 EPS by 8c

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021 7:00 AM EST

Strong Commercial Execution for Second Full Year of TIBSOVO® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 

Sale of Oncology Portfolio Expected to Close Around March 31 Subject to March 25 Shareholder Vote, Allowing Agios to Focus on Genetically Defined Diseases

Company Outlines Pivotal Development Program for Mitapivat in Sickle Cell Disease, Enabling a Potential Broad Label by Year-end 2026

Darrin Miles Appointed to Role of Chief Commercial Officer

CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:... More